Eligible patients can now begin Leqembi treatment at home, potentially reducing repeated infusion-center visits while preserving essential medical supervision and safety monitoring.
Over 50% of people with dementia have evidence of more than one type of dementia. A South Korean trial is testing Lilly’s Alzheimer’s drug Kisunla in people with both Lewy body dementia and Alzheimer’s. Success could open a new chapter in treating mixed dementia.
A Different Kind of Alzheimer’s Drug Just Delivered One of the Most Interesting Results in Years
COCHRANE SERIES, PART 1 – WHAT HAPPENED:
A respected review called a breakthrough Alzheimer’s drug useless. Experts shrugged. Investors, who normally panic on such news, barely noticed. Here’s why that matters — and what it means for families weighing their options.
In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Could Leqembi be given faster and more easily in the future? The new Biogen–Alteogen deal suggests it’s possible—but it doesn’t confirm changes to Leqembi. Here’s what professionals and families should understand.
A new study suggests that very low sodium intake may be linked to faster memory decline in older adults.
New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
EYE-OPENING TEEPA-CARE VIDEO:
Teepa Snow shows how to “say it right” – and not dish out upsetting words – to people with dementia. Get great tips from a well-known expert in this brilliant presentation.
MEDICATION VIDEO + ARTICLE: From allergies to moods, most of us get relief from drugs known as “anticholinergics”. Some raise dementia risk, some don’t. Do we always need them? A study of 300,000 people offers answers to help you and your doctor better weigh the risks and benefits.
Nature provides some of the best therapies for Alzheimer’s. Daffodils specifically from Wales are a big source of Galanthamine for Alzheimer’s. Rosemary competes head-on with the Alzheimer’s drug donepezil. Learn more about these natural sources.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
